Millennium Management Portfolio holdings
Millennium Management, founded in 1989 by Israel (Izzy) Englander and Ronald Shear and headquartered in New York City, is a global multi-strategy hedge fund managing over $71 billion in assets as of late 2024, employing a decentralized model with over 300 independent trading teams. Operating across equities, fixed income, commodities, currencies, and derivatives, the firm uses a mix of quantitative and fundamental strategies, providing its portfolio managers with capital, infrastructure, and autonomy to pursue diverse investment approaches while enforcing strict risk management. With more than 5,400 employees across offices in London, Hong Kong, Singapore, and beyond, Millennium has evolved from its initial $35 million seed capital—partly from the Belzberg family—into a titan of the hedge fund world, known for its ability to attract top talent and deliver consistent returns. Under Englander’s leadership as chairman and CEO, the firm remains a low-profile yet highly influential force in global finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PPL
PPL Corp
PPL
|
+$304M |
| 2 |
SWN
Southwestern Energy Company
SWN
|
+$207M |
| 3 |
Biogen
BIIB
|
+$177M |
| 4 |
MON
Monsanto Co
MON
|
+$164M |
| 5 |
BNY
Bank of New York Mellon
BNY
|
+$153M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$412M |
| 2 |
Pfizer
PFE
|
+$283M |
| 3 |
Devon Energy
DVN
|
+$194M |
| 4 |
Valero Energy
VLO
|
+$187M |
| 5 |
Altria Group
MO
|
+$174M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14% |
| 2 | Energy | 11.19% |
| 3 | Financials | 8.75% |
| 4 | Consumer Discretionary | 8.58% |
| 5 | Industrials | 8.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
CALL
Neurocrine Biosciences
NBIX
$16.8B
| $14.3M | 0.03% |
+300,000
| New | +$12.7M |
|
777
Mid-America Apartment Communities
MAA
$15.4B
| $14.3M | 0.03% |
196,451
+26,904
| +16% | +$2.03M |
|
778
Alcoa
AA
$11.9B
| $14.3M | 0.03% |
532,793
-794,256
| -60% | -$24.6M |
|
779
Glacier Bancorp
GBCI
$6.42B
| $14.2M | 0.03% |
481,462
-1,218,160
| -72% | -$33.4M |
|
|
KKD
780
DELISTED
KRISPY KREME DOUGHNUTS INC
KKD
| $14.1M | 0.03% |
+733,369
| New | +$13.6M |
|
781
Civeo
CVEO
$345M
| $14.1M | 0.03% |
382,799
+319,354
| +503% | +$14.4M |
|
782
John Wiley & Sons Class A
WLY
$2.65B
| $14.1M | 0.03% |
259,327
+95,412
| +58% | +$5.54M |
|
|
TTPH
783
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $14.1M | 0.03% |
14,859
+2,778
| +23% | +$2.27M |
|
784
Broadridge
BR
$17.8B
| $14.1M | 0.03% |
281,854
+242,706
| +620% | +$12.9M |
|
|
AAMI
785
Acadian Asset Management
AAMI
$3.08B
| $14.1M | 0.03% |
792,192
+435,133
| +122% | +$8.25M |
|
786
PTC Therapeutics
PTCT
$5.68B
| $14M | 0.03% |
+291,441
| New | +$17M |
|
|
EXPR
787
DELISTED
Express, Inc.
EXPR
| $14M | 0.03% |
38,625
-14,979
| -28% | -$5.23M |
|
788
Brixmor Property Group
BRX
$9.67B
| $14M | 0.03% |
604,683
-3,618,198
| -86% | -$88.2M |
|
789
Celldex Therapeutics
CLDX
$2.99B
| $14M | 0.03% |
36,898
-101,133
| -73% | -$40.2M |
|
|
VIAB
790
DELISTED
Viacom Inc. Class B
VIAB
| $13.9M | 0.03% |
215,690
+72,711
| +51% | +$4.92M |
|
|
NPKI
791
NPK International
NPKI
$1.06B
| $13.9M | 0.03% |
1,710,777
-1,452,979
| -46% | -$13.5M |
|
|
CBM
792
DELISTED
Cambrex Corporation
CBM
| $13.9M | 0.03% |
316,460
-250,479
| -44% | -$10.4M |
|
793
American Water Works
AWK
$26.7B
| $13.9M | 0.03% |
285,715
+214,055
| +299% | +$11.3M |
|
|
VAL
794
DELISTED
Valspar
VAL
| $13.9M | 0.03% |
169,784
-487,448
| -74% | -$40.9M |
|
795
Mattel
MAT
$4.38B
| $13.9M | 0.03% |
539,446
-2,434,627
| -82% | -$64.1M |
|
796
PUT
DNOW Inc
DNOW
$2.58B
| $13.8M | 0.03% |
694,100
-129,300
| -16% | -$2.96M |
|
|
797
Valero Energy
VLO
$90.1B
| $13.8M | 0.03% |
220,581
-3,169,902
| -93% | -$187M |
|
798
James River Group Holdings
JRVR
$208M
| $13.8M | 0.03% |
533,200
-140,579
| -21% | -$3.37M |
|
|
ACOR
799
DELISTED
Acorda Therapeutics
ACOR
| $13.8M | 0.03% |
3,445
-3,631
| -51% | -$14M |
|
800
Vanda Pharmaceuticals
VNDA
$307M
| $13.8M | 0.03% |
1,083,759
-515,403
| -32% | -$5.56M |
|
Similar funds
Millennium Management's Q2 2015 Portfolio in Review
As of Q2 2015, Millennium Management held 4,294 positions worth $52.9B, down 1.6% from $53.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Millennium Management's Q2 2015 filing shows 780 new, 1,199 increased, 1,223 reduced and 1,034 closed positions. Its largest new stake was Charter Communications: 575,958 shares worth $98.6M. The largest sale was Teva Pharmaceuticals, an estimated $412M.
By sector, the portfolio is most concentrated in Healthcare at 14% of assets, down from 15% a quarter earlier, followed by Energy and Financials.
- Millennium Management's largest Q2 2015 buy was Charter Communications: 575,958 shares worth $98.6M.
- Millennium Management added most to PPL Corp in Q2 2015, an estimated $304M increase.
- Millennium Management's biggest Q2 2015 reduction was Teva Pharmaceuticals, cutting an estimated $412M.
- Millennium Management fully exited SALIX PHARMACEUTICALS LTD DEL in Q2 2015, selling an estimated $145M.
- Millennium Management's ten largest holdings make up 11% of its $52.9B portfolio in Q2 2015.
- Millennium Management opened 780 new positions and closed 1,034 in Q2 2015.
- Millennium Management's portfolio value fell 1.6% quarter-over-quarter to $52.9B.
Based on Millennium Management's 13F filing for Q2 2015, filed 14 Aug 2015.